Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis

References

• Janossy G., Panayi G., Duke O., Bofill M., Poulter L. W., Goldstein G. Rheumatoid arthritis: a disease of T‐lymphocyte/macrophage immunoregulation. Lancet 1981; 2: 839–42
   PubMed Web of Science ®Google Scholar
• Walsh D. A. Angiogenesis and arthritis. Rheumatology (Oxford) 1999; 38: 103–12
   PubMed Web of Science ®Google Scholar
• Koch A. E. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003; 62((Suppl 2))ii60–7
   PubMed Web of Science ®Google Scholar
• Van Doornum S., McColl G., Wicks I. P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 2002; 46: 862–73
   PubMed Web of Science ®Google Scholar
• Gabriel S. E., Crowson C. S., Kremers H. M., Doran M. F., Turesson C., O'Fallon W. M., et al. Survival in rheumatoid arthritis: a population‐based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 54–8
   PubMed Web of Science ®Google Scholar
• Van Doornum S., Brand C., King B., Sundararajan V. Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2061–8
   PubMedGoogle Scholar
• Sihvonen S., Korpela M., Laippala P., Mustonen J., Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population‐based study. Scand J Rheumatol 2004; 33: 221–7
   PubMed Web of Science ®Google Scholar
• Solomon D. H., Karlson E. W., Rimm E. B., Cannuscio C. C., Mandl L. A., Manson J. E., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303–7
   PubMed Web of Science ®Google Scholar
• Solomon D. H., Goodson N. J., Katz J. N., Weinblatt M. E., Avorn J., Setoguchi S., et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1608–12
   PubMed Web of Science ®Google Scholar
• Gonzalez‐Gay M. A., Gonzalez‐Juanatey C., Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8–17
   PubMed Web of Science ®Google Scholar
• Del Rincon I., Williams K., Stern M. P., Freeman G. L., O'Leary D. H., Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48: 1833–40
   PubMed Web of Science ®Google Scholar
• Del Rincon I., O'Leary D. H., Freeman G. L., Escalante A. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis, 2006 Nov 9 [Epub ahead of print] (doi: 10.1016/j.atherosclerosis.2006.09.027)
   Google Scholar
• Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138(5 Pt 2): S419–20
   Google Scholar
• Ribatti D. The discovery of endothelial progenitor cells. An historical review. Leuk Res 2007; 31: 439–44
   PubMed Web of Science ®Google Scholar
• Werner N., Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy?. Arterioscler Thromb Vasc Biol 2006; 26: 257–66
   PubMed Web of Science ®Google Scholar
• Aicher A., Zeiher A. M., Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension 2005; 45: 321–5
   PubMed Web of Science ®Google Scholar
• Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435–9
   PubMed Web of Science ®Google Scholar
• Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9–22
   PubMed Web of Science ®Google Scholar
• Breier G., Clauss M., Risau W. Coordinate expression of vascular endothelial growth factor receptor‐1 (flt‐1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 1995; 204: 228–39
   PubMed Web of Science ®Google Scholar
• Millauer B., Wizigmann‐Voos S., Schnurch H., Martinez R., Moller N. P., Risau W., et al. High affinity VEGF binding and developmental expression suggest Flk‐1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835–46
   PubMed Web of Science ®Google Scholar
• Fong G. H., Rossant J., Gertsenstein M., Breitman M. L. Role of the Flt‐1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66–70
   PubMed Web of Science ®Google Scholar
• Shalaby F., Rossant J., Yamaguchi T. P., Gertsenstein M., Wu X. F., Breitman M. L., et al. Failure of blood‐island formation and vasculogenesis in Flk‐1‐deficient mice. Nature 1995; 376: 62–6
   PubMed Web of Science ®Google Scholar
• Ferrara N., Carver‐Moore K., Chen H., Dowd M., Lu L., O'Shea K. S., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439–42
   PubMed Web of Science ®Google Scholar
• Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964–7
   PubMed Web of Science ®Google Scholar
• Kawamoto A., Gwon H. C., Iwaguro H., Yamaguchi J. I., Uchida S., Masuda H., et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001; 103: 634–7
   PubMed Web of Science ®Google Scholar
• Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221–8
   PubMed Web of Science ®Google Scholar
• Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells. EMBO J 1999; 18: 3964–72
   PubMed Web of Science ®Google Scholar
• Murayama T., Tepper O. M., Silver M., Ma H., Losordo D. W., Isner J. M., et al. Determination of bone marrow‐derived endothelial progenitor cell significance in angiogenic growth factor‐induced neovascularization in vivo. Exp Hematol 2002; 30: 967–72
   PubMed Web of Science ®Google Scholar
• Hattori K., Dias S., Heissig B., Hackett N. R., Lyden D., Tateno M., et al. Vascular endothelial growth factor and angiopoietin‐1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001; 193: 1005–14
   PubMed Web of Science ®Google Scholar
• Kalka C., Masuda H., Takahashi T., Gordon R., Tepper O., Gravereaux E., et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86: 1198–202
   PubMed Web of Science ®Google Scholar
• Moore M. A., Hattori K., Heissig B., Shieh J. H., Dias S., Crystal R. G., et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector‐mediated elevation of serum levels of SDF‐1, VEGF, and angiopoietin‐1. Ann N Y Acad Sci 2001; 938: 36–47
   PubMed Web of Science ®Google Scholar
• Ceradini D. J., Kulkarni A. R., Callaghan M. J., Tepper O. M., Bastidas N., Kleinman M. E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF‐1 induction of SDF‐1. Nat Med 2004; 10: 858–64
   PubMed Web of Science ®Google Scholar
• Grunewald M., Avraham I., Dor Y., Bachar‐Lustig E., Itin A., Jung S., et al. VEGF induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006; 124: 175–89
   PubMed Web of Science ®Google Scholar
• Vasa M., Fichtlscherer S., Aicher A., Adler K., Urbich C., Martin H., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1–7
   PubMed Web of Science ®Google Scholar
• Hill J. M., Zalos G., Halcox J. P., Schenke W. H., Waclawiw M. A., Quyyumi A. A., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593–600
   PubMed Web of Science ®Google Scholar
• Walter D. H., Haendeler J., Reinhold J., Rochwalsky U., Seeger F., Honold J., et al. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ Res 2005; 97: 1142–51
   PubMed Web of Science ®Google Scholar
• Schmidt‐Lucke C., Rossig L., Fichtlscherer S., Vasa M., Britten M., Kamper U., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981–7
   PubMed Web of Science ®Google Scholar
• Werner N., Kosiol S., Schiegl T., Ahlers P., Walenta K., Link A., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999–1007
   PubMed Web of Science ®Google Scholar
• Heeschen C., Lehmann R., Honold J., Assmus B., Aicher A., Walter D. H., et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004; 109: 1615–22
   PubMed Web of Science ®Google Scholar
• Paleolog E. M., Hunt M., Elliott M. J., Feldmann M., Maini R. N., Woody J. N. Deactivation of vascular endothelium by monoclonal anti‐tumur necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39: 1082–91
   PubMed Web of Science ®Google Scholar
• Herbrig K., Haensel S., Oelschlaegel U., Pistrosch F., Foerster S., Passauer J. Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells. Ann Rheum Dis 2006; 65: 157–63
   PubMed Web of Science ®Google Scholar
• Bainbridge J., Sivakumar B., Paleolog E. Angiogenesis as a therapeutic target in arthritis: lessons from oncology. Curr Pharm Des 2006; 12: 2631–44
   PubMed Web of Science ®Google Scholar
• Sivakumar B., Harry L. E., Paleolog E. M. Modulating angiogenesis: more vs less. J Am Med Assoc 2004; 292: 972–7
   PubMed Web of Science ®Google Scholar
• Sivakumar B., Paleolog E. Immunotherapy of rheumatoid arthritis: past, present and future. Curr Opin Drug Discov Dev 2005; 8: 169–76
   PubMedGoogle Scholar
• Koch A. E., Harlow L. A., Haines G. K., Amento E. P., Unemori E. N., Wong W. L., et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152: 4149–56
   PubMed Web of Science ®Google Scholar
• Fava R. A., Olsen N. J., Spencer‐Green G., Yeo K. T., Yeo T. K., Berse B., et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180: 341–6
   PubMed Web of Science ®Google Scholar
• Paleolog E. M., Young S., Stark A. C., McCloskey R. V., Feldmann M., Maini R. N. Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL‐1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1258–65
   PubMed Web of Science ®Google Scholar
• Ballara S. C., Taylor P. C., Reusch P., Marmé D., Feldmann M., Maini R. N., et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001; 44: 2055–64
   PubMed Web of Science ®Google Scholar
• Miotla J., Maciewicz R., Kendrew J., Feldmann M., Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen‐induced arthritis. Lab Invest 2000; 80: 1195–205
   PubMed Web of Science ®Google Scholar
• Afuwape A., Feldmann M., Paleolog E. Adenoviral delivery of soluble VEGF receptor 1 (sFlt‐1) abrogates disease activity in murine collagen‐induced arthritis. Gene Therapy 2003; 10: 1950–1960
   PubMed Web of Science ®Google Scholar
• Lu J., Kasama T., Kobayashi K., Yoda Y., Shiozawa F., Hanyuda M., et al. Vascular endothelial growth factor expression and regulation of murine collagen‐induced arthritis. J Immunol 2000; 164: 5922–7
   PubMed Web of Science ®Google Scholar
• Sone H., Kawakami Y., Sakauchi M., Nakamura Y., Takahashi A., Shimano H., et al. Neutralization of vascular endothelial growth factor prevents collagen‐induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 2001; 281: 562–8
   PubMed Web of Science ®Google Scholar
• Luttun A., Tjwa M., Moons L., Wu Y., Angelillo‐Scherrer A., Liao F., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti‐Flt1. Nat Med 2002; 8: 831–40
   PubMed Web of Science ®Google Scholar
• De Bandt M., Ben Mahdi M. H., Ollivier V., Grossin M., Dupuis M., Gaudry M., et al. Blockade of vascular endothelial growth factor receptor I (VEGF‐RI), but not VEGF‐RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol 2003; 171: 4853–9
   PubMed Web of Science ®Google Scholar
• Hurlimann D., Forster A., Noll G., Enseleit F., Chenevard R., Distler O., et al. Anti‐tumor necrosis factor‐alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184–7
   PubMed Web of Science ®Google Scholar
• circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci7923649Gonzalez‐Juanatey C., Testa A., Garcia‐Castelo A., Garcia‐Porrua C., Llorca J., Gonzalez‐Gay M. A. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long‐term treatment with anti‐tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51: 447–50
   PubMedGoogle Scholar
• Cardillo C., Schinzari F., Mores N., Mettimano M., Melina D., Zoli A., et al. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther 2006; 80: 275–81
   PubMed Web of Science ®Google Scholar
• Dessein P. H., Joffe B. I., Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R634–43
   PubMed Web of Science ®Google Scholar
• Ruger B., Giurea A., Wanivenhaus A. H., Zehetgruber H., Hollemann D., Yanagida G., et al. Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 2004; 50: 2157–66
   PubMed Web of Science ®Google Scholar
• Hirohata S., Yanagida T., Nampei A., Kunugiza Y., Hashimoto H., Tomita T., et al. Enhanced generation of endothelial cells from CD34+ cells of the bone marrow in rheumatoid arthritis: possible role in synovial neovascularization. Arthritis Rheum 2004; 50: 3888–96
   PubMed Web of Science ®Google Scholar
• Kurosaka D., Yasuda J., Yoshida K., Yasuda C., Toyokawa Y., Yokoyama T., et al. Kinetics of circulating endothelial progenitor cells in mice with type II collagen arthritis. Blood Cells Mol Dis 2005; 35: 236–40
   PubMedGoogle Scholar
• Grisar J., Aletaha D., Steiner C. W., Kapral T., Steiner S., Seidinger D., et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005; 111: 204–11
   PubMed Web of Science ®Google Scholar
• Ablin J. N., Boguslavski V., Aloush V., Elkayam O., Paran D., Caspi D., et al. Effect of anti‐TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci 2006; 79: 2364–9
   PubMed Web of Science ®Google Scholar
• Popa C., Netea M. G., Radstake T., Van der Meer J. W., Stalenhoef A. F., van Riel P. L., et al. Influence of anti‐tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303–5
   PubMed Web of Science ®Google Scholar
• Jacobsson L. T., Turesson C., Gulfe A., Kapetanovic M. C., Petersson I. F., Saxne T., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213–18
   PubMed Web of Science ®Google Scholar
• Grisar J. C., Aletaha D., Steiner C. W., Kapral T., Steiner S., Saemann M., et al. Endothelial progenitor cells in active rheumatoid arthritis: effects of TNF and of glucocorticoid therapy. Ann Rheum Dis 2007 2007
   Google Scholar
• Seeger F. H., Haendeler J., Walter D. H., Rochwalsky U., Reinhold J., Urbich C., et al. p38 mitogen‐activated protein kinase downregulates endothelial progenitor cells. Circulation 2005; 111: 1184–91
   PubMed Web of Science ®Google Scholar